Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00744471 · ClinicalTrials.gov registry record · Phase 3

Tanezumab in Osteoarthritis Of The Hip

A Phase 3 study, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
627
Enrollment target

NCT00744471 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 627 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00744471, a Phase 3 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
627 participants
Enrollment target

Study Summary

The purpose of this study is to test the efficacy and safety of 3 doses of tanezumab in osteoarthritis of the hip in patients

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL tanezumab

Trial Details

FieldValue
Enrollment Target 627 participants
Start Date 2008-11-17
Est. Completion 2010-08-13
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00744471

The ClinicalTrials.gov registry entry for NCT00744471 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 627 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00744471 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00744471 about?

NCT00744471 is a clinical study titled "Tanezumab in Osteoarthritis Of The Hip". The purpose of this study is to test the efficacy and safety of 3 doses of tanezumab in osteoarthritis of the hip in patients

What is the current status of trial NCT00744471?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 627 participants. The study started on 2008-11-17. Estimated completion is 2010-08-13.

What interventions are being tested in trial NCT00744471?

The interventions under investigation include: Placebo (BIOLOGICAL), tanezumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00744471?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.